Cidara Therapeutics Q3 2023 Earnings Report $20.92 -0.27 (-1.27%) As of 01/14/2025 04:00 PM Eastern Earnings HistoryForecast Cidara Therapeutics EPS ResultsActual EPS-$1.80Consensus EPS -$2.80Beat/MissBeat by +$1.00One Year Ago EPSN/ACidara Therapeutics Revenue ResultsActual Revenue$12.72 millionExpected Revenue$8.02 millionBeat/MissBeat by +$4.70 millionYoY Revenue GrowthN/ACidara Therapeutics Announcement DetailsQuarterQ3 2023Date11/2/2023TimeN/AConference Call ResourcesCDTX Earnings History Cidara Therapeutics Earnings HeadlinesCidara Therapeutics Inc CDTXDecember 28, 2024 | morningstar.comCidara Therapeutics files to sell 7.04M shares of common stock for holdersDecember 23, 2024 | markets.businessinsider.com3 golden rules for dividends Legend Jack Carter just revealed his entire strategy for building a passive income formula through “profit sharing”... Including 5 specific tickers to consider owning TODAY And he fully breaks down his 3 “golden ratios” for buying passive income stocks. These aren’t just theoretical rules, either. Jack revealed that the vast majority of his income capital is deployed in a specific set of stocks that meet this criteria. And not only does he explain the rules behind his approach…January 15, 2025 | ProsperityPub (Ad)Twelve option delistings on December 23rdDecember 23, 2024 | markets.businessinsider.comRBC Capital Initiates Coverage of Cidara Therapeutics (CDTX) with Outperform RecommendationDecember 14, 2024 | msn.comCidara achieves full enrolment in influenza prevention trialDecember 6, 2024 | finance.yahoo.comSee More Cidara Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cidara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cidara Therapeutics and other key companies, straight to your email. Email Address About Cidara TherapeuticsCidara Therapeutics (NASDAQ:CDTX), a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.View Cidara Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Infosys (1/16/2025)Bank of America (1/16/2025)U.S. Bancorp (1/16/2025)Morgan Stanley (1/16/2025)The PNC Financial Services Group (1/16/2025)Taiwan Semiconductor Manufacturing (1/16/2025)UnitedHealth Group (1/16/2025)Schlumberger (1/17/2025)Truist Financial (1/17/2025)Netflix (1/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
